

**In the Claims:**

1. (Previously Presented) A composition based on plant extracts, with an anti-oxidant activity which is useful for the treatment of adiposity and cellulitis in humans, wherein said composition comprises:
  - biflavones of *Ginkgo biloba*,
  - catechine and/or epicatechine,
  - cumarine or derivatives thereof,
  - iodine, and
  - a component chosen from among madecassic acid, asiatic acid, asiaticoside and mixtures of these.
2. (Previously Presented) A composition according to Claim 1, wherein said composition is obtained by mixing plant extracts.
3. (Previously Presented) A composition according to Claim 2, wherein said extracts are in phytosomal form.
4. (Previously Presented) A composition according to claim 1 wherein said composition further includes flavonol glucosides and lactonic terpenes.
5. (Previously Presented) A composition according to claim 1 wherein said composition also includes a compound chosen from the group consisting of methylxanthinic derivatives, chlorogenic acids, mono- and di-caffeoylchonic acid and derivatives thereof, eicosapentaenoic acid, docohexaenoic acid, gamma-linolenic acid and mixtures thereof.
6. (Previously Presented) A composition according to claim 1 wherein said composition is obtained by mixing plant extracts in the following percentages by weight:
  - 1.5-32% of *Ginkgo biloba* biflavone extract;
  - 6-80% of leucocyanidine;

1.5-32% of *Melilotus* and/or *Aesculus hyppocastanum* extract;  
1.5-32% of centella extract;  
1.5-85% extract of *Fucus vesiculosus*.

7. (Previously Presented) A composition according to Claim 6, further comprising one or more of the following relative to 100 parts of said composition:
  - from 1.5 to 32% by weight of *Ilex paraguariensis* extract;
  - from 1.5 to 32% by weight of artichoke extract;
  - from 5 to 80% by weight of fish oil; and
  - from 30 to 120% by weight of borage oil.
8. (Previously Presented) A composition according to claim 1 which includes:
  - 0.12-12% by weight of total biflavones;
  - 0.2-12% by weight of catechine and/or epicatechine;
  - 0.15-7% by weight of coumarin and derivatives thereof;
  - 0.25-15% by weight of asiaticoside;
  - 0.25-22% by weight of asiatic acid and/or madecassic acid; and
  - up to 0.5% of iodine.
9. (Previously Presented) A composition according to Claim 8, further comprising one or more of the following components:
  - from 0.05 to 2.5% by weight of caffeine;
  - from 0.05 to 4.8% by weight of caffeoylcholic acids;
  - from 0.75 to 24% by weight of eicosapentaenoic acid;
  - from 0.6 to 8% by weight of docosahexaenoic acid; and
  - from 2.5 to 22% by weight of gamma-linolenic acid.
10. (Previously Presented) A composition according to claim 1 in a pharmaceutical form suitable for oral administration to a human.
11. (Cancelled)

12. (Previously Presented) A composition according to claim 6 further comprising 1.5-32 wt% of standardised *Ginkgo biloba* extract containing flavone glucosides and lactonic terpenes.
13. (Previously Presented) A composition according to claim 8 which comprises:
  - 0.5-6% by weight of total biflavones;
  - 0.5-8% by weight of catechine and/or epicatechine;
  - 0.3-3.5% by weight of coumarin and derivatives thereof;
  - 0.5-7.5% by weight of asiaticoside; and
  - 0.5-11% by weight of asiatic acid and/or madecassic acid.
14. (Previously Presented) A composition according to claim 8 which further comprises:
  - 0.25-12% by weight of flavonol glucosides and
  - 0.1-2% by weight of lactonic terpenes.
15. (Previously Presented) A composition according to claim 14 comprising:
  - 0.5-6% by weight of flavonol glucosides, and
  - 0.2-1% by weight, of lactonic terpenes.
16. (Previously Presented) A composition according to claim 9 comprising:
  - 0.1-1% by weight of caffeine;
  - 0.1-2.5% by weight of caffeilchinnic acids;
  - 1.5-12% by weight of eicosapentaenoic acid;
  - 1.2-4% by weight of docosahexaenoic acid; and
  - 5 to 11% by weight of gamma-linolenic acid.
17. (Amended) A method for treating adiposity and cellulites in a human with steps that comprise administering to a human suffering from adiposity or cellulitis an effective amount of a composition ~~comprising a flavone dimer~~ according to claim 1.

18. (Amended) A method according to claim 17 wherein ~~said flavone dimer is a biflavone extract of *Ginkgo biloba*~~ the administering step comprises administering an effective amount of a composition according to claim 6.
19. (Previously Presented) A method according to claim 18 wherein ~~said biflavone extract comprises amentoflavone, bilobectine, isoginkgetine, ginkgetine, or sciadopisitin~~ the administering step comprises administering a composition according to claim 7.
20. (Previously Presented) A method according to claim 19 wherein ~~said composition further comprises a flavonol glucoside or a lactonic terpene~~ the administering step comprises administering a composition according to claim 8.